Trial of Image-Guided Cochlear Implant Programming Versus Standard of Care
NCT ID: NCT02815124
Last Updated: 2022-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2021-12-31
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Image-guided Cochlear Implant Programming (IGCIP)
NCT03306082
Pediatric Image-Guided Cochlear Implant Programming
NCT03886168
Balance in Children With Cochlear Implants
NCT03620500
Percutaneous Cochlear Implantation: Implementation of Technique
NCT01460823
Voice Guard Processing Evaluation in a Cohort of Subjects Implanted With the Neuro Cochlear Implant System
NCT03256097
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In recent years much attention has focused on the interface between the cochlear implant electrodes and the auditory neurons they are stimulating. Technological improvements at Vanderbilt in imaging processing have made it possible to determine the location of each electrode array in relationship to the frequency spectrum of the cochlea.
Using this information, the investigators have developed a new method of CI programming which they call image-guided cochlear implant programming, or IGCIP in which sub-optimally placed electrodes are turned-off or deactivated. Sub-optimally placed electrodes are defined as ones for which their neighboring electrodes are in closer proximity to the site of their neural stimulation. By deactivating sub-optimally positioned electrodes, channel interaction is reduced allowing a cleaner signal to be presented to the auditory nerve.
The investigators have implemented this strategy on 133 CIs of post-lingually deafened (hearing loss after the ability to speak) adult CI users with median use of their CI's with SOC programming of 1.3 years (range 0.3-15.5). When trialing IGCIP, mean word scores increased from 48.8±23.7% to 53.3±22.8% correct, and mean sentence scores increased from 62.2±28.5% to 65.0±26.9% correct. Both of these finding were statistically significant. Extracting out the pre-lingually (hearing loss before the ability to speak) deafened adults, the investigators see that for word scores, 24 of the 133 (28%) had statistically significant improvement 12 of the 133 (9%) had statistically significant decline, and the remaining 97 (73%) had equivocal results. Similarly, for the sentence scores, 36 of the 133 (27%) had statistically significant improvement 24 of the 133 (18%) had statistically significant decline, and the remaining 73 (55%) had equivocal results.
Perhaps the most important metric is which map patients select for long term use - SOC or IGCIP. Ninety-six of the 133 (72.1%) participants elected to keep IGCIP for long term use despite prior research that shows that there is a bias for CI recipients to favor their original map over a new map. And, for the 28% for elected to keep their SOC map, the process involves no risk - the deactivated electrodes are simply reactivated. Given these exciting prospective findings, the investigators are now proposing a randomized controlled trial (RCT) for newly activated adult CI recipients with both the CI user and testing audiologist blinded as to program (SOC or IGCIP). The investigators hypothesize that CI recipients randomized to IGCIP will have improved hearing performance as assessed by both word and sentence testing.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard of Care
Cochlear Implant programming using standard of care
Standard of Care
Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Standard of Care
Image-Guided Cochlear Implant Programming
Cochlear Implant programming using Image-Guided Cochlear Implant Programming
Image-Guided Cochlear Implant Programming
Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Image-Guided Cochlear Implant Programming
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard of Care
Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Standard of Care
Image-Guided Cochlear Implant Programming
Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Image-Guided Cochlear Implant Programming
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pre-lingual onset of deafness
* Mini-Mental State Exam \< 24 (to remove cognitive decline as a confounding variable)
* Congenital inner ear malformation as detected on pre-operative CT scan performed as routine care
* Non-English speaking (because our audiological speech testing battery is validated for English speakers)
* Have undergone cochlear implantation outside of the Vanderbilt system
* Pregnancy which is a contraindication for elective CT scanning and surgery
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Vanderbilt University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Robert F. Labadie
Vice Chair, Chief Research Officer, Professor of Otolaryngology-Head and Neck Surgery, Professor of Biomedical Engineering
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert F. Labadie, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Vanderbilt University Medical Center
Benoit M. Dawant, PhD
Role: STUDY_CHAIR
Vanderbilt University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
160461
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.